Last reviewed · How we verify
conventional mood stabilizers
At a glance
| Generic name | conventional mood stabilizers |
|---|---|
| Sponsor | Shanghai Mental Health Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Dayingpian Treating Bipolar Disorder
- 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression (PHASE2)
- Adjuvant Psychotherapy for Relapse Prevention in Early Adulthood (< 35 yr.) of Bipolar Disorder (NA)
- Comparative Effectiveness Study for Bipolar Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |